The most effective measure to prevent tuberculosis disease is to treat latent (asymptomatic) infections as described in the Treatment section. The IGRA test is the most reliable method for detecting latent infections, although the PPD skin test is also used.
The incidence of tuberculosis began to decrease markedly even before the advent of drug therapy in the 1940s. This is attributed to better housing and nutrition, which have improved host resistance. At present, prevention of the spread of the organism depends largely on the prompt identification and adequate treatment of patients who are coughing up the organism. The use of masks and other respiratory isolation procedures to prevent spread to medical personnel is also important. Contact tracing of individuals exposed to patients with active pulmonary disease who are coughing should be done.
An important component of prevention is the use of the PPD skin test to detect recent converters and to institute treatment for latent infections as described earlier. Groups that should be screened with the PPD skin test include people with HIV infection, close contacts of patients with active tuberculosis, low-income populations, persons with alcohol use disorder and those who inject drugs, prison inmates, and foreign-born individuals from countries with a high incidence of tuberculosis.
Because there are some problems associated with PPD skin tests, such as the measurement and the interpretation of results and the inconvenience of the patient having to return for the skin test to be read, a laboratory test to detect latent infections was developed. This IGRA test measures the amount of interferon-γ released from the patient’s lymphocytes after exposure to antigens from M. tuberculosis in cell culture. The test requires only a single blood specimen and determines the amount of interferon-γ by an enzyme-linked immunosorbent assay (ELISA) test.
BCG vaccine can be used to induce partial resistance to tuberculosis. The vaccine contains a strain of live, attenuated M. bovis called BCG. The vaccine is effective in preventing the appearance of tuberculosis as a clinical disease, especially in children, although it does not prevent infection by M. tuberculosis. However, a major problem with the vaccine is its variable effectiveness, which can range from 0% to 70%. It is used primarily in areas of the world where the incidence of the disease is high. It is not usually used in the United States because of its variable effectiveness and because the incidence of the disease is low enough that it is not cost-effective.
The skin test reactivity induced by the vaccine given to children wanes with time, and the interpretation of the skin test reaction in adults is not altered by the vaccine. For example, skin test reactions of 10 mm or more should not be attributed to the vaccine unless it was administered recently. In the United States, use of the vaccine is limited to young children who are in close contact with individuals with active tuberculosis and to military personnel. BCG vaccine should not be given to immunocompromised people because the live BCG organisms can cause disseminated disease.
BCG vaccine is also used to treat bladder cancer. The vac cine is instilled into the bladder and serves to nonspecifically stimulate cell-mediated immunity, which can inhibit the growth of the carcinoma cells.
As an alternative to BCG vaccine, a trial vaccine containing two recombinant M. tuberculosis proteins as immunogen was shown to be effective in preventing active disease.
Pasteurization of milk and destruction of infected cattle are important in preventing intestinal tuberculosis.